IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Direct medical costs of asthma management in a Nigerian tertiary institution

Author: KOSISOCHI AMORHA, BARTHOLOMEW NNANYERE ADOBEZE, MATHEW JEGBEFUME OKONTA
Abstract: To determine the direct medical cost of asthma management in a tertiary health Institution in Nigeria. This was a retrospective, observational study conducted using the medical records of asthma patients of the University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu State within 1st January, 2011 to 31st December, 2016. Data were extracted from the patients’ folders using a pro-forma document and analyzed using the IBM Statistical Product for Services Solution (SPSS) for Windows, Version 21.0. The direct medical cost of asthma management in UNTH from 2011 to 2016 was ?2,635,078.77 representing ?7,180.05 per asthma prescription encountered. The controller inhalers, Seretide® diskus® (50/100 and 50/250), accounted for the highest total costs with ?630,000.00 and ?318,920.00 respectively. Amoxicillin/Clavulanic acid (625mg) was the most prescribed antibiotic and spirometry was the highest of the investigational tests. Drugs were responsible for 82.49% of the total direct cost of asthma management. The lowest direct medical costs attributable to asthma were recorded in year 2014 while the highest was recorded in 2016. The exchange rate was $1 to ?356, as of the time of the study. The direct medical cost of asthma management for the study period was about ?2.6 million representing ?7,180.05 per asthma prescription encountered. The controller inhalers containing salmeterol/fluticasone (50/100 and 50/250), accounted for the highest total costs. Drugs accounted for more than three-quarter of the total direct costs.
Keyword: asthma, direct medical cost, Nigeria
DOI: https://doi.org/10.31838/ijpr/2018.10.03.069
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free